Protocol D3251C00003: A randomised, double-blind, placebo-controlled, parallel group, multicentre, phase lll study to evaluate the efficacy and safety of 2 doses of benralizumab (MEDI-563) in patients with severe to very severe Chronic Obstructive Pulmon

Project: Other project

StatusFinished
Effective start/end date9/10/149/9/18

Funding

  • AstraZeneca LP: $9,091.57